436 Studies Now Enrolling
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
| Sponsor: | National Cancer Institute NIH DHHS |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAT7825 |
| U.S. Govt. ID: | NCT04137107 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your colorectal cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN).
This study is closed
Do You Qualify?
| Are you 25 years of age or older? | Yes | No |
| Are you being treated for colorectal cancer? | Yes | No |
| Are you experiencing peripheral neuropathy (numbness, tingling, or pain in your hands and feet) as a result of your treatment? | Yes | No |
| Are you able to make extra visits to the clinic for treatment and assessments? | Yes | No |